The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying bla(KPC-2). However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime-avibactam. Methods: The activity of imipenem-releba...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp-Wallace, Krisztina M., Barnes, Melissa D., Taracila, Magdalena A., Bethel, Christopher R., Rutter, Joseph D., Zeiser, Elise T., Young, Katherine, Bonomo, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215400/
https://www.ncbi.nlm.nih.gov/pubmed/37237794
http://dx.doi.org/10.3390/antibiotics12050892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215400/
https://www.ncbi.nlm.nih.gov/pubmed/37237794
http://dx.doi.org/10.3390/antibiotics12050892

Ejemplares similares